Insights

Home » Insights » Insights Intercept Blood System

Categories

see all
Cerus 22/04/2020

When you live in times when every platelet concentrate counts

With the outbreak of COVID-19 maintaining adequate inventory levels for platelet concentrates may be even more challenging than ever.
Cerus 27/02/2020

Pathogen inactivation of blood components during outbreaks of infectious diseases in the European Union

The European Centre for Disease Prevention and Control (ECDC), in co-operation with the Italian National Blood Centre, organized an expert consultation meeting (April 2019) to discuss the potential role of pathogen inactivation technologies (PI) as a blood safety intervention during outbreaks of infectious diseases for which (in most cases) laboratory screening of blood donations is not...
Cerus 31/01/2020

First annual haemovigilance activity report released after universal implementation of INTERCEPT in France

Pathogen inactivation of platelet concentrates (PC) with the INTERCEPTTM Blood System has been universally implemented in metropolitan France from November 2017 onwards. Previously INTERCEPT had been deployed since 2006 in Alsace and in the French overseas departments.
Cerus 29/01/2020

Coronavirus Inactivation Reported in INTERCEPT Blood System Publication in Transfusion Medicine

A study (Hashem AM, Hassan AM, Tolah AM, Alsaadi MA, Abunada Q, Damanhouri GA, El-Kafrawy SA, Picard-Maureau M, Azhar EI, Hindawi SI. Amotosalen and ultraviolet A light efficiently inactivate MERS-coronavirus in human platelet concentrates. Transfus Med 2019, following prior publications on the inactivation of the MERS coronavirus in human plasma and the inactivation of the SARS (Severe Acute...

Guidelines 30/10/2019

FDA Publishes New Guidance Document on Mitigating Bacterial Contamination in Platelet Components

The FDA’s final guidance document on mitigating bacterial contamination in platelet components, released on September 30, 2019, formally recognises the risk of transfusion-transmitted bacterial infections and the need for additional safety measures to protect patients.
Cerus 23/10/2019

First confirmed infections from West Nile virus in Germany

The West Nile virus (WNV) is an enveloped RNA virus, well-known since 1937. Originally from Africa, it has now reached temperate climate zones. The virus mainly infects birds, but can also be transmitted to humans by mosquitoes – or by contaminated blood products!

Ask an Expert

Do you have questions about the INTERCEPT™ Blood System, blood safety or blood transfusions? The INTERCEPT team has plenty of knowledge and expertise.

Ask an Expert

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 00157 v43.0